Key Investor Signals
Raised £1.4M to commercialize AI-ECG research
Imperial reported £1.4M in funding in June 2026, with Twin Path Ventures leading the pre-seed backing.
Validated mortality risk across five external cohorts
AIRE was developed on 1,163,401 ECGs from 189,539 patients. Across five external cohorts, mortality C-indices were 0.638–0.773.
Validated models for future valve-disease risk
Models were developed in 400,882 patients and tested externally in 34,214 US patients. Internal C-indices for future valve disease were 0.691–0.793; external testing supported the findings.
Team
Boroumand Zeidaabadi
Co-founder & CEO
- Earned a first-class cardiovascular-sciences BSc at Imperial, with the Agnes Cope Prize for first place in the course.
- Won Heart Rhythm Society and International Society of Electrocardiology young-investigator awards in 2025.
- Received a British Heart Foundation MBPhD studentship in 2024 for AI-enhanced electrocardiography research.
Arunashis Sau
Co-founder & CSO
- Completed a British Heart Foundation clinical research fellowship in AI-ECG cardiovascular risk prediction from 2021–2024.
- First-authored the 2024 AIRE mortality and cardiovascular risk study published in The Lancet Digital Health.
- Trained as a cardiology registrar and academic clinical fellow in the North West Thames programme before the spinout.
Fu Siong Ng
Co-founder & CMO
- Built an Imperial cardiac-electrophysiology research group and secured a five-year British Heart Foundation programme grant.
- Practises invasive cardiac ablation and implants pacemakers and defibrillators as a consultant cardiologist in NHS hospitals.
- Completed an Imperial PhD and Washington University postdoctoral research investigating arrhythmias in explanted human hearts.
Libor Pastika
Co-founder & CTO
- MRC-funded clinical researcher at Imperial College London, developing AI-ECG models to predict cardiometabolic disease.
- Pioneered ECG-based models of body mass index and introduced delta-BMI as a cardiometabolic risk marker.
- Won an American Heart Association early-career investigator award in 2024 and two ESC Preventive Cardiology investigator awards in 2025.
Product
Cardiovolt analyzes routine 12-lead ECG recordings using neural networks trained on linked patient outcomes. Separate models detect existing disease and estimate future risk; survival models use the signal to produce patient-specific estimates of how risk changes over time.
Reusing standard ECG recordings
The software accepts digital ECG waveforms or images from standard clinical recordings. It is designed to add an analysis layer to existing equipment rather than requiring another recording device.
Detecting and predicting disease
Different models address present disease and future events such as heart failure or valve disease. Risk-ranking performance in published studies is measured with a C-index, not a percentage of correctly diagnosed patients.
Supporting follow-up decisions
The intended output helps clinicians prioritize further investigation and follow-up. Confirmatory imaging remains part of the care pathway; the company explicitly states that the software is not yet ready for clinical use.
Market Overview
Cardiovolt addresses the commercial market for AI analysis of cardiac tests. Hospitals and diagnostic providers buy tools that interpret ECGs or imaging, identify patients needing further tests and support care decisions. The broader category includes software, hardware and services rather than ECG algorithms alone.
Its commercial route depends on fitting existing ECG workflows and demonstrating useful clinical decisions, not just retrospective model discrimination.
Worldwide AI-in-cardiology revenue in 2025, including software, hardware and services.
Forecast annual growth in AI-in-cardiology revenue from 2026 to 2033.
Diagnostic applications generated about 40% of AI-in-cardiology revenue in 2025.
North America generated 46.8% of worldwide AI-in-cardiology revenue in 2025.
Comparable Outcomes
BioTelemetry
Provided remote cardiac diagnostics and monitoring through wearable monitors, software and services. Acquired by Philips in 2021 for $2.8B. The business combined ambulatory ECG monitoring, diagnostic services and an established clinical network.
Heartflow
Developed AI software that analyzes coronary CT scans to help diagnose and manage coronary artery disease. Completed its Nasdaq IPO in August 2025, raising $364.2M gross.
Interested in More Startups Like Cardiovolt.ai?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.